賓夕法尼亞費(fèi)城2021年10月1日 /美通社/ -- 在中美兩地運(yùn)營的生物科技公司,安派科生物醫(yī)學(xué)科技有限公司(“安派科生物”或“該公司” 或“我們”)(納斯達(dá)克股票代碼:ANPC),今天宣布其截至2021年6月30日的上半年未經(jīng)審計(jì)的財(cái)務(wù)業(yè)績。
財(cái)務(wù)亮點(diǎn)
業(yè)務(wù)亮點(diǎn)
安派科生物首席執(zhí)行官兼董事長俞昌(Chris Yu)博士說道:“我們對(duì)上半年收入及商業(yè)化檢測量的顯著增長感到非常滿意,這有力地表明了安派科生物的技術(shù)、服務(wù)和質(zhì)量正在得到認(rèn)可并受到市場的追捧。非GAAP虧損和2020年同期相比降低了18.3%??偟膩碚f,我們公司正朝著正確的方向前進(jìn)。此外,隨著我們推出性能改進(jìn)的第二代癌癥檢測傳感器以及啟動(dòng)新的癌癥治療項(xiàng)目,我們的研發(fā)工作繼續(xù)取得進(jìn)展。我們的CDA技術(shù)在我們正在進(jìn)行的普通大眾群體多癌癥風(fēng)險(xiǎn)評(píng)估檢測的后續(xù)隨訪中繼續(xù)顯示出令人興奮的結(jié)果。我們完全致力于創(chuàng)新和開發(fā)新產(chǎn)品和技術(shù),并與客戶密切合作以實(shí)現(xiàn)持續(xù)的增長?!?
有關(guān)使用非GAAP財(cái)務(wù)方法
Non-GAAP net loss is calculated as net income adjusted for change in fair value of convertible debts and stock-based compensation expense. The non-GAAP financial measures are presented to enhance investors’ overall understanding of the Company’s financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. Investors are encouraged to review the reconciliation of the historical non-GAAP financial measures to its most directly comparable GAAP financial measures. As non-GAAP financial measures have material limitations as analytical metrics and may not be calculated in the same manner by all companies, they may not be comparable to other similarly titled measures used by other companies. In light of the foregoing limitations, you should not consider non-GAAP financial measures as a substitute for, or superior to, such metrics in accordance with US GAAP.
Reconciliations of Non-GAAP Results |
||||||||||||
Reconciliations of Non-GAAP net loss |
||||||||||||
(All amounts in thousands, except share and per share data or otherwise stated) |
||||||||||||
For the six months ended |
||||||||||||
June 30, |
June 30, |
June 30, |
||||||||||
2020 |
2021 |
2021 |
||||||||||
RMB |
RMB |
US$ |
||||||||||
Net loss |
(56,077) |
(57,689) |
(8,937) |
|||||||||
Less: |
||||||||||||
Change in fair value of convertible debts |
(7,289) |
4,346 |
673 |
|||||||||
Stock based compensation expense |
17,548 |
15,897 |
2,462 |
|||||||||
Non-GAAP net loss |
(45,818) |
(37,446) |
(5,802) |
|||||||||